健友股份(603707.SH)：子公司获得美国FDA新药注射用磷霉素药品注册批件

Core Viewpoint - The company, Jianyou Co., Ltd. (健友股份), announced that its subsidiary, Meitheal Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for a new injectable drug, Phosphomycin, 6 g/vial, aimed at treating complex urinary tract infections, including acute pyelonephritis, and inhibiting the development of diseases caused by resistant bacteria [1]. Group 1 - The FDA approval is for Phosphomycin, which is indicated for the treatment of complex urinary tract infections [1]. - The drug is specifically designed to address acute pyelonephritis and combat antibiotic-resistant bacteria [1].